Vol 94, No 3 (2023)
Research paper
Published online: 2022-03-07

open access

Page views 2730
Article views/downloads 832
Get Citation

Connect on Social Media

Connect on Social Media

Effect of mucinous differentiation in endometrioid type endometrial cancers on prognosis

Bahadir Saatli1, Orkun Ilgen2, Selim Kandemir1, Seda Eryigit3, Meral Koyuncuoglu3, Cagnur Ulukus3, Erkan Cagliyan1
Pubmed: 35315013
Ginekol Pol 2023;94(3):183-187.


Objectives: To evaluate the influence of mucinous differentiation in endometrioid endometrial cancer regarding spread and prognosis.

Material and methods: Endometrioid endometrial cancer cases between 2015 and 2020 were collected retrospectively and divided into two groups according to the cytoplasmic mucin including. Prognostic factors and cancer spread related parameters were evaluated.

Results: A total of 219 patients were enrolled in this study. One hundred twenty-two (55.7%) were endometrioid and 97 (44.3%) were in the mucinous differentiated endometrioid catagory. Age was similar between the groups (59.3 vs 58.7, p = 0.62), however, grade 3 lesions were more frequent in endometrioid type endometrial cancer (8.7% vs 1.4%, p < 0.01). Poor prognostic factors including myometrial invasion, lymphovascular space invasion (LVSI), lymph node metastases, peritoneal cytology, endocervical involvement, and stage were not significantly different between groups (p = 0.23, p = 0.49, p = 0.40, p = 0.15, p = 0.17, p = 0.55). The median overall survival time of endometrioid and mucinous differentiated endometrioid type endometrial cancer patients was determined 88.5 and 96.8 months, respectively (p = 0.46).

Conclusions: Mucinous differentiation in the endometrioid type of endometrial cancer does not seem to affect the prognosis in endometrioid endometrial cancer patients.

Article available in PDF format

View PDF Download PDF file


  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424.
  2. Göksedef BPÇ, Akbayır O, Corbacıoğlu A, et al. Comparison of preoperative endometrial biopsy grade and final pathologic diagnosis in patients with endometrioid endometrial cancer. J Turk Ger Gynecol Assoc. 2012; 1;13(2): 106–110.
  3. Mao W, Wei S, Yang H, et al. Clinicopathological study of organ metastasis in endometrial cancer. Future Oncol. 2020; 16(10): 525–540.
  4. Li Y, Cong P, Wang P, et al. Risk factors for pelvic lymph node metastasis in endometrial cancer. Arch Gynecol Obstet. 2019; 300(4): 1007–1013.
  5. Chan JK, Kapp DS, Cheung MK, et al. Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancer. Am J Obstet Gynecol. 2008; 198(2): 216.e1–216.e5.
  6. Mendivil A, Schuler KM, Gehrig PA. Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control. 2009; 16(1): 46–52.
  7. Sumangala G, Premalatha TS, Kulkarni K, et al. Uterine Papillary Serous Carcinoma—Still an Enigma? Indian J Gynecol Oncol. 2017; 15(1): 11.
  8. Duzguner S, Turkmen O, Kimyon G, et al. Mucinous endometrial cancer: Clinical study of the eleven cases . North Clin Istanb. 2019; 3;7(1): 60–64.
  9. Kim KR, Robboy SJ. Mucinous Adenocarcinoma of the Endometrium. In: Deavers M, Coffey D. ed. Precision Molecular Pathology of Uterine Cancer. Molecular Pathology Library, vol 11. Springer, Cham 2017: 143–154.
  10. Galic V, Schiavone MB, Herzog TJ, et al. Prognostic significance of mucinous differentiation of endometrioid adenocarcinoma of the endometrium. Cancer Invest. 2013; 31(7): 500–504.
  11. Musa F, Huang M, Adams B, et al. Mucinous histology is a risk factor for nodal metastases in endometrial cancer. Gynecol Oncol. 2012; 125(3): 541–545.
  12. Gungorduk K, Ozdemir A, Ertas IE, et al. Is mucinous adenocarcinoma of the endometrium a risk factor for lymph node involvement? A multicenter case-control study. Int J Clin Oncol. 2015; 20(4): 782–789.
  13. Worley MJ, Davis M, Berhie SH, et al. Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma. Gynecol Oncol. 2014; 135(1): 54–57.
  14. Abdulfatah E, Sakr S, Morris RT, et al. Mucinous differentiation is predictive of improved outcomes in low-grade endometrioid carcinoma. Gynecol Oncol. 2017; 1(145): 121–122.